Cyclophosphamide, tetrahydropyranyl-adriamycin, and cis-platinum in the treatment of head and neck adenocarcinoma.
Cyclophosphamide, tetrahydropyranyl-adriamycin, and cis-platinum in the treatment of head and neck adenocarcinoma.
复制标题
环磷酰胺、四氢吡喃阿霉素和顺铂治疗头颈腺癌。
DOI：
10.1016/s0385-8146(89)80037-9
复制
发表时间：
1989
期刊：
影响因子：
--
通讯作者：
T. Hosokawa
中科院分区：
文献类型：
--
作者：
A. Kida;T. Furusaka;S. Endo;H. Iida;T. Hosokawa
12例晚期或复发性头颈部腺癌患者接受了环磷酰胺（C）、四氢吡喃阿霉素（T）和顺铂（P）（CTP）或环磷酰胺、阿霉素（A）和顺铂（CAP）联合化疗方案。环磷酰胺（300 mg/m2）、四氢吡喃阿霉素（30 mg/m2）或阿霉素（30 mg/m2）、顺铂（50 mg/m2），每日静脉滴注。9例患者接受CTP方案，3例患者接受CAP方案。在化疗之前，5名患者接受了手术或放射治疗，其他7名患者没有接受特殊治疗。完全缓解7例，缓解时间2 ~ 18个月，平均6.8个月;部分缓解2例，缓解时间2个月。几乎所有患者均出现恶心和呕吐。7例患者出现脱发;然而，CTP方案患者的脱发较少（如果有的话）。观察到轻度或中度白细胞减少症和贫血，但没有患者需要停止治疗。CTP方案和CAP方案对头颈部腺癌的治疗均有重要价值。
Twelve patients with advanced or relapsed head and neck adenocarcinoma received a combination chemotherapy regimen of either cyclophosphamide (C), tetrahydropyranyl-adriamycin (T), andcis-platinum (P) (CTP) or cyclophosphamide, adriamycin (A), andcis-platinum (CAP). Cyclophosphamide (300 mg/sq m), eithert etrahydropyranyl-adriamycin (30 mg/sq m) or adriamycin (30 mg/sq m), andcis-platinum (50 mg/sq m) were administered intravenously in a single day. Nine patients received the CTP regimen, and three patients, the CAP regimen. Prior to chemotherapy, five patients had received surgery or radiation therapy, and the other seven patients received no special treatment. A response rate 75%, was achieved (9/12); there were 7 complete responses, whose duration was a mean 6.8 months, ranging from 2 to 18 months, and 2 partial responses, whose duration was 2 months. Virtually all patients experienced nausea and vomiting. Alopecia developed in 7 patients; however, the patients with the CTP regimen experienced less alopecia, if any. Leucopenia and anemia of either a slight or moderate degree were observed, but there was no patient for whom it was necessary to discontinue the treatment. Both CTP and CAP regimens appear to be of significant value in controlling head and neck adenocarcinoma.